MedTrace Logo

Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors

NCT04287218 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-09-12

No results posted yet for this study

Summary

Cognitive therapy has been shown to reduce fear of cancer recurrence (FCR), mainly in breast cancer survivors. The accessibility of cognitive behavioural interventions could be further improved by Internet delivery, but self-guided interventions have shown limited efficacy. The aim of this study is to test the efficacy of a therapist guided internet-delivered intervention (TG-iConquerFear) vs. augmented treatment as usual (aTAU) in Danish colorectal cancer survivors.

Conditions

Interventions

BEHAVIORAL

TG-iConquerFear

The theoretical frame of iConquerFear is based on the Common-Sense Model of illness, the Self-Regulatory Executive Function model and Relational Frame Theory. The intervention includes elements of attention training, increasing metacognitive awareness, acceptance \& mindfulness, promotion of appropriate screening behavior, and values-based goal setting. The electronic platform comprises 5 modules containing educational text, interactive exercises, short videos featuring doctors, therapists and patients' perspectives.

BEHAVIORAL

aTAU

Active control group

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Centre for Oncology Education and Research Translation (CONCERT), Australia

    collaborator UNKNOWN

  • Danish Cancer Society

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Lars Henrik Jensen, MD, PhD · Vejle Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-07-01
Completion
2026-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04287218 on ClinicalTrials.gov